Start or continue cancer treatment
Another round of chemotherapy, immunotherapy or targeted therapy, alongside symptom care.
In trials of advanced esophageal and gastric cancer, 81.3% of treatment groups kept overall health status stable over time.
Applies to: 43 randomized trials, 13,727 people with advanced esophageal or gastric cancer. Not limited to the last months of life.
After first-line treatment, single-drug taxane chemotherapy and several targeted drugs improved quality of life compared with supportive care alone.
Applies to: 43 randomized trials, 13,727 people with advanced esophageal or gastric cancer. Not limited to the last months of life.
Among people who were still functioning well, those on chemotherapy had worse quality of life in their last week than those not on it (odds ratio 0.35).
Applies to: 312 US adults with progressive metastatic cancer after at least one chemotherapy regimen, followed until death. Observational.
14% of people on palliative chemotherapy had CPR or a breathing machine in their last week, compared with 2% of those not on it.
Applies to: 386 US adults with metastatic cancer that had not responded to at least one regimen, judged terminally ill, who died. Observational, with statistical adjustment.
People on palliative chemotherapy more often died in intensive care (11% vs 2%) and less often at home (47% vs 66%).
Applies to: 386 US adults with metastatic cancer that had not responded to at least one regimen, judged terminally ill, who died. Observational, with statistical adjustment.
69% of people with lung cancer and 81% with colorectal cancer on chemotherapy did not report understanding that it was not at all likely to cure them.
Applies to: 1193 US adults receiving chemotherapy for newly diagnosed stage IV lung or colorectal cancer.
SourcedUS national prospective cohort study (CanCORS) · 2012
People given immunotherapy in their last 30 days enrolled in hospice less often (45% vs 69%) and died in hospital more often (56% vs 29%).
Applies to: 157 people who received immune checkpoint inhibitors and died, at one US center, 2015 to 2018.
Immunotherapy in the last month was not linked to more emergency visits or hospital stays, but was linked to dying in hospital (43% vs 16%).
Applies to: 102 people who received immune checkpoint inhibitors and died, at two Irish cancer centers.